File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Scopus: eid_2-s2.0-0027394517
- PMID: 8095442
- WOS: WOS:A1993KR84400044
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Alpha-adrenergic receptor responsiveness in vascular smooth muscle of canine bone
Title | Alpha-adrenergic receptor responsiveness in vascular smooth muscle of canine bone |
---|---|
Authors | |
Issue Date | 1993 |
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.corronline.com/ |
Citation | Clinical Orthopaedics And Related Research, 1993 n. 287, p. 286-291 How to Cite? |
Abstract | In an ex vivo canine tibial preparation, an alpha-1-adrenergic antagonist (prazosin, 212 ng · ml-1 · minute-1) markedly attenuated the effect of high intraluminal doses (greater than 0.5 mg) of norepinephrine but was less effective at lower doses. An alpha-2-adrenergic antagonist (rauwolscine, 198 ng/ml/minute) was more effective than prazosin in blocking the vascular smooth muscle contraction evoked by low doses of norepinephrine (greater than 0.125 mg). Cirazoline, an alpha-1-adrenergic agonist, had a potent contractile effect on smooth muscle at high concentrations (5 x 10-6 M), whereas the alpha-2-adrenergic agonist UK14304 was more effective at low concentrations (1 x 10-7 M). Thus, in the vascular smooth muscle of canine tibia there is a mixed population of postjunctional alpha-1 and alpha-2- adrenergic receptors that exhibits a dose-dependent responsiveness. Adrenergic receptor mechanisms may contribute to alterations in bone blood flow. This may be relevant to impaired reperfusion after microvascular bone transfer. Furthermore, adrenergic receptor mechanisms may help explain variations in bone blood flow related to systemic, regional humoral, or metabolic factors. |
Persistent Identifier | http://hdl.handle.net/10722/171102 |
ISSN | 2023 Impact Factor: 4.2 2023 SCImago Journal Rankings: 1.387 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ye, Z | en_US |
dc.contributor.author | Wood, MB | en_US |
dc.contributor.author | Vanhoutte, PM | en_US |
dc.date.accessioned | 2012-10-30T06:12:11Z | - |
dc.date.available | 2012-10-30T06:12:11Z | - |
dc.date.issued | 1993 | en_US |
dc.identifier.citation | Clinical Orthopaedics And Related Research, 1993 n. 287, p. 286-291 | en_US |
dc.identifier.issn | 0009-921X | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/171102 | - |
dc.description.abstract | In an ex vivo canine tibial preparation, an alpha-1-adrenergic antagonist (prazosin, 212 ng · ml-1 · minute-1) markedly attenuated the effect of high intraluminal doses (greater than 0.5 mg) of norepinephrine but was less effective at lower doses. An alpha-2-adrenergic antagonist (rauwolscine, 198 ng/ml/minute) was more effective than prazosin in blocking the vascular smooth muscle contraction evoked by low doses of norepinephrine (greater than 0.125 mg). Cirazoline, an alpha-1-adrenergic agonist, had a potent contractile effect on smooth muscle at high concentrations (5 x 10-6 M), whereas the alpha-2-adrenergic agonist UK14304 was more effective at low concentrations (1 x 10-7 M). Thus, in the vascular smooth muscle of canine tibia there is a mixed population of postjunctional alpha-1 and alpha-2- adrenergic receptors that exhibits a dose-dependent responsiveness. Adrenergic receptor mechanisms may contribute to alterations in bone blood flow. This may be relevant to impaired reperfusion after microvascular bone transfer. Furthermore, adrenergic receptor mechanisms may help explain variations in bone blood flow related to systemic, regional humoral, or metabolic factors. | en_US |
dc.language | eng | en_US |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.corronline.com/ | en_US |
dc.relation.ispartof | Clinical Orthopaedics and Related Research | en_US |
dc.subject.mesh | Adrenergic Alpha-Agonists - Pharmacology | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Dogs | en_US |
dc.subject.mesh | Dose-Response Relationship, Drug | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Muscle Contraction - Drug Effects | en_US |
dc.subject.mesh | Muscle, Smooth, Vascular - Chemistry - Drug Effects | en_US |
dc.subject.mesh | Norepinephrine - Pharmacology | en_US |
dc.subject.mesh | Prazosin - Pharmacology | en_US |
dc.subject.mesh | Quinoxalines - Pharmacology | en_US |
dc.subject.mesh | Receptors, Adrenergic, Alpha - Analysis - Drug Effects | en_US |
dc.subject.mesh | Regional Blood Flow | en_US |
dc.subject.mesh | Tibia - Blood Supply | en_US |
dc.subject.mesh | Yohimbine - Pharmacology | en_US |
dc.title | Alpha-adrenergic receptor responsiveness in vascular smooth muscle of canine bone | en_US |
dc.type | Article | en_US |
dc.identifier.email | Vanhoutte, PM:vanhoutt@hku.hk | en_US |
dc.identifier.authority | Vanhoutte, PM=rp00238 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.pmid | 8095442 | - |
dc.identifier.scopus | eid_2-s2.0-0027394517 | en_US |
dc.identifier.issue | 287 | en_US |
dc.identifier.spage | 286 | en_US |
dc.identifier.epage | 291 | en_US |
dc.identifier.isi | WOS:A1993KR84400044 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Ye, Z=7401957016 | en_US |
dc.identifier.scopusauthorid | Wood, MB=7403448994 | en_US |
dc.identifier.scopusauthorid | Vanhoutte, PM=7202304247 | en_US |
dc.identifier.issnl | 0009-921X | - |